Bu-Fei decoction and modified Bu-Fei decoction inhibit the growth of non-small cell lung cancer, possibly via inhibition of apurinic/apyrimidinic endonuclease 1

Jiang,Shan‑Tong; Han,Shu‑Yan; Pang,Li‑Na; Jiao,Yan‑Na; He,Xi‑Ran; Li,Ping‑Ping

doi:10.3892/ijmm.2018.3444

Bu-Fei decoction and modified Bu-Fei decoction inhibit the growth of non-small cell lung cancer, possibly via inhibition of apurinic/apyrimidinic endonuclease 1

Authors:
- Shan‑Tong Jiang
- Shu‑Yan Han
- Li‑Na Pang
- Yan‑Na Jiao
- Xi‑Ran He
- Ping‑Ping Li
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Integration of Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, P.R. China
Published online on: January 30, 2018 https://doi.org/10.3892/ijmm.2018.3444
Pages: 2128-2138
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human apurinic/apyrimidinic endonuclease 1 (APE1) is a ubiquitous multifunctional protein, which possesses DNA repair and redox activities. High levels of APE1 are associated with chemo‑ and radioresistance, and poor prognosis in various types of cancer, including non‑small cell lung cancer (NSCLC). Bu‑Fei decoction (BFD) is a traditional Chinese herbal formula, which is believed to supplement Qi, clear away heat and nourish the lungs. BFD and modified Bu‑Fei decoction (MBFD) have been used in China to treat patients with lung cancer. The present study aimed to evaluate the potential antitumor effects of BFD and MBFD on NSCLC in vitro and in vivo. In addition, the possible contribution of APE1 was examined. MTT assay was used to investigated the anti-tumor activity of BFD and MBFD on H1975 and H292 NSCLC cell lines. The DNA damage of cells in the control and the experimental groups was detected using comet assay. The in vivo anti-tumor effects of BFD and MBFD were evaluated in a NSCLC tumor nude mouse xenograft model. Polymerase chain reaction (PCR), reverse transcription‑quantitative PCR (RT‑qPCR) analysis and western blot analysis were applied to analyze the mRNA and protein expression levels of APE1 in H1975 and H292 cells, so as to the xenograft tumor tissues. The concentration of APE1 in mice plasma was determined using enzyme linked immunosorbent assay (ELISA). In vitro, BFD and MBFD inhibited the growth of cultured H1975 and H292 NSCLC cells. The results of a comet assay revealed that BFD and MBFD increased DNA damage. Furthermore, the expression levels of APE1 were decreased in response to BFD and MBFD at the mRNA and protein levels. In mice carrying NSCLC xenografts, BFD and MBFD inhibited tumor growth and decreased APE1 expression. In addition, in normal human lung bronchial epithelial BEAS‑2B cells, the half maximal inhibitory concentrations of BFD and MBFD were much higher compared with in NSCLC cells, and they had no effect on DNA damage. These results suggested that BFD and MBFD may inhibit the growth of NSCLC, possibly by inhibiting APE1 expression.

View Figures

View References

1	Kastan MB: DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res. 6:517–524. 2008. View Article : Google Scholar : PubMed/NCBI
2	Rodriguez-Rocha H, Garcia-Garcia A, Panayiotidis MI and Franco R: DNA damage and autophagy. Mutat Res. 711:158–166. 2011. View Article : Google Scholar : PubMed/NCBI
3	Altieri F, Grillo C, Maceroni M and Chichiarelli S: DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal. 10:891–937. 2008. View Article : Google Scholar : PubMed/NCBI
4	Christmann M, Tomicic MT, Roos WP and Kaina B: Mechanisms of human DNA repair: An update. Toxicology. 193:3–34. 2003. View Article : Google Scholar : PubMed/NCBI
5	Roos WP, Thomas AD and Kaina B: DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 16:20–33. 2016. View Article : Google Scholar
6	Wilson DM III and Bohr VA: The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst). 6:544–559. 2007. View Article : Google Scholar
7	Bhakat KK, Mantha AK and Mitra S: Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid Redox Signal. 11:621–638. 2009. View Article : Google Scholar
8	Li M and Wilson DM III: Human apurinic/apyrimidinic endonuclease 1. Antioxid Redox Signal. 20:678–707. 2014. View Article : Google Scholar :
9	Wood RD, Mitchell M, Sgouros J and Lindahl T: Human DNA repair genes. Science. 291:1284–1289. 2001. View Article : Google Scholar : PubMed/NCBI
10	Luo M, He H, Kelley MR and Georgiadis MM: Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal. 12:1247–1269. 2010. View Article : Google Scholar :
11	Robertson KA, Bullock HA, Xu Y, Tritt R, Zimmerman E, Ulbright TM, Foster RS, Einhorn LH and Kelley MR: Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 61:2220–2225. 2001.PubMed/NCBI
12	Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY and Zhang YS: APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer. 66:298–304. 2009. View Article : Google Scholar : PubMed/NCBI
13	Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, et al: Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: Possible prognostic significance. Mol Med. 13:89–96. 2007. View Article : Google Scholar : PubMed/NCBI
14	Kakolyris S, Kaklamanis L, Engels K, Fox SB, Taylor M, Hickson ID, Gatter KC and Harris AL: Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. Br J Cancer. 77:1169–1173. 1998. View Article : Google Scholar : PubMed/NCBI
15	Mahjabeen I, Ali K and Zhouxand Kayani MA: Deregulation of base excision repair gene expression and enhanced proliferation in head and neck squamous cell carcinoma. Tumour Biol. 35:5971–5983. 2014. View Article : Google Scholar : PubMed/NCBI
16	Poletto M, Di Loreto C, Marasco D, Poletto E, Puglisi F, Damante G and Tell G: Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers. Biochem Biophys Res Commun. 424:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
17	Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF, et al: Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 9:901–909. 2015. View Article : Google Scholar : PubMed/NCBI
18	Qing Y, Wang D, Lei X, Xiang DB, Li MX, Li ZP and Shan JL: The expression of APE1 and its correlation with prognostic significance after 252Cf radiotherapy in cervical cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 40:125–128. 2009.In Chinese. PubMed/NCBI
19	Sheng Q, Zhang Y, Wang R, Zhang J, Chen B, Wang J, Zhang W and Xin X: Prognostic significance of APE1 cytoplasmic localization in human epithelial ovarian cancer. Med Oncol. 29:1265–1271. 2012. View Article : Google Scholar
20	Tell G, Damante G, Caldwell D and Kelley MR: The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal. 7:367–384. 2005. View Article : Google Scholar : PubMed/NCBI
21	Chantre-Justino M, Alves G, Britto C, Cardoso A, Scherrer L, Moreira Ados S, Quirino R, Ornellas A, Leitão A and Lage C: Impact of reduced levels of APE1 transcripts on the survival of patients with urothelial carcinoma of the bladder. Oncol Rep. 34:1667–1674. 2015. View Article : Google Scholar : PubMed/NCBI
22	Jiang Y, Zhou S, Sandusky GE, Kelley MR and Fishel ML: Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest. 28:885–895. 2010. View Article : Google Scholar : PubMed/NCBI
23	Dai N, Cao XJ, Li MX, Qing Y, Liao L, Lu XF, Zhang SH, Li Z, Yang YX and Wang D: Serum APE1 autoantibodies: A novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer. PLoS One. 8:e580012013. View Article : Google Scholar : PubMed/NCBI
24	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
25	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
26	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
27	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
28	Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol. 30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
29	Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al PROFILE 1014 Investigators: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
30	National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®). Non-Small Cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
31	Piao BK, Tang WX, Zhang ZQ, Lin HS, Duan FW and Yu GQ: The observation of Feiliuping ointment treatment of advanced lung cancer-with 339 cases of clinical analysis. J Tradit Chin Med. 21–23. 1991.
32	Li PW, Zhang DZ and Hao YX: Clinical analysis of Ping-Fei decoction treatment of 109 cases of non-small cell lung cancer. J Tradit Chin Med. 87–88. 1995.
33	Yang GW, Wang XM, Han D, et al: Study on TCM comprehensive therapy in treatment of advanced Non-Small Cell Lung Cancer. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi. 12:11–13. 2005.In Chinese.
34	Han Y, Wang H, Xu W, Cao B, Han L, Jia L, Xu Y, Zhang Q, Wang X, Zhang G, et al: Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement Ther Med. 24:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
35	Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH and Mao ZJ: Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial. Complement Ther Med. 24:55–62. 2016. View Article : Google Scholar : PubMed/NCBI
36	Li W, Chen C, Saud SM, Geng L, Zhang G, Liu R and Hua B: Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment. BMC Complement Altern Med. 14:1532014. View Article : Google Scholar : PubMed/NCBI
37	He XR, Han SY, Li XH, Zheng WX, Pang LN, Jiang ST and Li PP: Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo. J Ethnopharmacol. 204:45–57. 2017. View Article : Google Scholar : PubMed/NCBI
38	Pang L, Han S, Jiao Y, Jiang S, He X and Li P: Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation. Int J Oncol. 51:25–38. 2017. View Article : Google Scholar : PubMed/NCBI
39	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
40	Guide for the care and use of laboratory animals. 8th. The National Academies Press; Washington, USA:
41	Zhou N, Han SY, Zhou F and Li PP: Antitumor effect of Shu-Gan-Liang-Xue decoction in breast cancer is related to the inhibition of aromatase and steroid sulfatase expression. J Ethnopharmacol. 154:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
42	Zhang QJ and Xu XP: The application of Bu-Fei decoction in lung deficiency symptom. Hubei Journal of Traditional Chinese Medicine. 34:1999.
43	Ke MY, Li XF and Li RH: Bu-Fei decoction treatment of 32 cases of advanced lung cancer. Fujian Journal of Traditional Chinese Medicine. 21:1995.
44	Cheng XD, Hou CH, Zhang XJ, Xie HY, Zhou WY, Yang L, Zhang SB and Qian RL: Effects of Huangqi (Hex) on inducing cell differentiation and cell death in K562 and HEL cells. Acta Biochim Biophys Sin (Shanghai). 36:211–217. 2004. View Article : Google Scholar
45	Shen YJ: Pharmacology of Traditional Chinese Medicine. 1st. People’s Medical Publishing House; Beijing, China: 2000
46	Gao XM: Pharmacy. China Press of Traditional Chinese Medicine; Beijing, China: 2007
47	Kuo YJ, Yang JS, Lu CC, Chiang SY, Lin JG and Chung JG: Ethanol extract of Hedyotis diffusa willd upregulates G0/G1 phase arrest and induces apoptosis in human leukemia cells by modulating caspase cascade signaling and altering associated genes expression was assayed by cDNA microarray. Environ Toxicol. 30:1162–1177. 2015. View Article : Google Scholar
48	Lee HZ, Bau DT, Kuo CL, Tsai RY, Chen YC and Chang YH: Clarification of the phenotypic characteristics and Antitumor activity of Hedyotis diffusa. Am J Chin Med. 39:201–213. 2011. View Article : Google Scholar
49	Shoemaker M, Hamilton B, Dairkee SH, Cohen I and Campbell MJ: In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother Res. 19:649–651. 2005. View Article : Google Scholar : PubMed/NCBI
50	Gong T, Wang CF, Yuan JR, Li Y, Gu JF, Zhao BJ, Zhang L, Jia XB, Feng L and Liu SL: Inhibition of Tumor Growth and immunomodulatory effects of flavonoids and scutebarbatines of Scutellaria barbata D Don in Lewis-bearing C57BL/6 mice. Evid Based Complement Alternat Med. 2015:6307602015. View Article : Google Scholar
51	Shiau AL, Shen YT, Hsieh JL, Wu CL and Lee CH: Scutellaria barbata inhibits angiogenesis through downregulation of HIF-1 α in lung tumor. Environ Toxicol. 29:363–370. 2014. View Article : Google Scholar
52	Yin X, Zhou J, Jie C, Xing D and Zhang Y: Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549. Life Sci. 75:2233–2244. 2004. View Article : Google Scholar : PubMed/NCBI